Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
HOME > BUSINESS
BUSINESS
- ViiV Receives Approval for HIV Infection Treatment Triumeq
March 17, 2015
- Takecab Surged to Top Spot in January Anterio Ranking
March 16, 2015
- Meiji Seika Halts Development of Antiallergic Treatment, Terminating Pact with Amalyte
March 16, 2015
- Eisai Revises Deal with Epizyme on Cancer Therapies
March 13, 2015
- Santen Earns Approval for Preservative-Free Glaucoma Eye Drops
March 13, 2015
- Sanwa Kagaku Names Hata as Successor to Late President Yamamoto
March 13, 2015
- AZ Appoints BMKK’s Taniguchi as Head of R&D
March 13, 2015
- AZ Receives Approval for Bydureon Pen Formulation
March 13, 2015
- Takecab vs PPIs (3): Which Will Come Out on Top? Everything Now in the Hands of Frontline Prescribers
March 13, 2015
- Takeda Transfers HPV Vaccine License to Kaketsuken
March 12, 2015
- Takecab vs PPIs (2): Takecab to Initially Gain Share for H. pylori Eradication?
March 12, 2015
- AZ to Tap Rich Pipelines to Grow as Oncology Powerhouse
March 11, 2015
- Over Half of RA Patients Remained in Remission 1 Year After Stopping Enbrel: Prof. Yamanaka
March 11, 2015
- Alogliptin Demonstrates No Increased Risk of Heart Failure: Takeda
March 11, 2015
- University of Tokyo, Sanofi Collaborate for Joint Drug Discovery Research in Fields of Inflammatory Disease, Oncology
March 11, 2015
- Takecab vs PPIs (1): “Rapid, Sustained Efficacy” Pitted against “Patient Satisfaction”, Will Paradigm Shift Occur?
March 11, 2015
- Announcement: 8th Annual Marketing Excellence Japan 2015 - Westin Tokyo, May 12-13
March 10, 2015
- Astellas Wins US Approval for Antifungal Agent Cresemba
March 10, 2015
- Ethical Drug Sales Down 0.1% in January: Crecon Report
March 10, 2015
- 74 Drug Makers Paid 483.1 Billion Yen to Healthcare Providers in FY2013: Jiho Tally
March 9, 2015
ページ
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…